

François Mouton-Liger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1519905/publications.pdf>

Version: 2024-02-01

25
papers

1,051
citations

430874

18
h-index

580821

25
g-index

25
all docs

25
docs citations

25
times ranked

1624
citing authors

#	ARTICLE	IF	CITATIONS
1	Oxidative stress increases BACE1 protein levels through activation of the PKR-eIF2 γ pathway. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012, 1822, 885-896.	3.8	139
2	Parkin deficiency modulates NLRP3 inflammasome activation by attenuating an A β -dependent negative feedback loop. <i>Glia</i> , 2018, 66, 1736-1751.	4.9	100
3	Increased levels of cerebrospinal fluid JNK3 associated with amyloid pathology: links to cognitive decline. <i>Journal of Psychiatry and Neuroscience</i> , 2015, 40, 151-161.	2.4	75
4	PINK1/Parkin-Dependent Mitochondrial Surveillance: From Pleiotropy to Parkinson's Disease. <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 120.	2.9	75
5	Neuroinflammation and A β Accumulation Linked To Systemic Inflammation Are Decreased By Genetic PKR Down-Regulation. <i>Scientific Reports</i> , 2015, 5, 8489.	3.3	70
6	Impact of cerebro-spinal fluid biomarkers of Alzheimer's disease in clinical practice: a multicentric study. <i>Journal of Neurology</i> , 2014, 261, 144-151.	3.6	56
7	Modulation of Tau Phosphorylation by the Kinase PKR: Implications in Alzheimer's Disease. <i>Brain Pathology</i> , 2011, 21, 189-200.	4.1	55
8	Increased Cerebrospinal Fluid Levels of Double-Stranded RNA-Dependant Protein Kinase in Alzheimer's Disease. <i>Biological Psychiatry</i> , 2012, 71, 829-835.	1.3	52
9	Cerebrospinal Fluid PKR Level Predicts Cognitive Decline in Alzheimer's Disease. <i>PLoS ONE</i> , 2013, 8, e53587.	2.5	46
10	The PKR Activator PACT Is Induced by A β : Involvement in Alzheimer's Disease. <i>Brain Pathology</i> , 2012, 22, 219-229.	4.1	40
11	PCP4 (PEP19) overexpression induces premature neuronal differentiation associated with Ca ²⁺ /Calmodulin-Dependent kinase II β activation in mouse models of down syndrome. <i>Journal of Comparative Neurology</i> , 2011, 519, 2779-2802.	1.6	39
12	STAT3 inhibition protects against neuroinflammation and BACE1 upregulation induced by systemic inflammation. <i>Immunology Letters</i> , 2020, 228, 129-134.	2.5	38
13	Are ketogenic diets promising for Alzheimer's disease? A translational review. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 42.	6.2	38
14	Effect of active A β immunotherapy on neurons in human Alzheimer's disease. <i>Journal of Pathology</i> , 2015, 235, 721-730.	4.5	31
15	Inverse association between CSF A β 42 levels and years of education in mild form of Alzheimer's disease: The cognitive reserve theory. <i>Neurobiology of Disease</i> , 2010, 40, 456-459.	4.4	30
16	Modulation of oxidative stress and tau phosphorylation by the mTOR activator phosphatidic acid in SH-SY5Y cells. <i>FEBS Letters</i> , 2011, 585, 1801-1806.	2.8	24
17	Who Needs Cerebrospinal Biomarkers? A National Survey in Clinical Practice. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 857-861.	2.6	22
18	Ketogenic diet therapy in Alzheimer's disease: an updated review. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2021, 24, 372-378.	2.5	22

#	ARTICLE	IF	CITATIONS
19	CSF A β 1-42 Levels and Glucose Metabolism in Alzheimer's Disease>. Journal of Alzheimer's Disease, 2011, 27, 845-851.	2.6	20
20	CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 88.	6.2	20
21	Developmental molecular and functional cerebellar alterations induced by PCP4/PEP19 overexpression: Implications for Down syndrome. Neurobiology of Disease, 2014, 63, 92-106.	4.4	17
22	Efficacy and Safety of Ketone Supplementation or Ketogenic Diets for Alzheimer's Disease: A Mini Review. Frontiers in Nutrition, 2021, 8, 807970.	3.7	17
23	Plasma neuregulin 1 as a synaptic biomarker in Alzheimer's disease: a discovery cohort study. Alzheimer's Research and Therapy, 2022, 14, .	6.2	12
24	The screening of Alzheimer's patients with CSF biomarkers, modulates the distribution of APOE genotype: impact on clinical trials. Journal of Neurology, 2014, 261, 1187-1195.	3.6	11
25	Biogenesis and regulation of microRNA: implication in Alzheimer's disease. Future Neurology, 2010, 5, 839-850.	0.5	2